TGF-β1-licensed murine MSCs show superior therapeutic efficacy in modulating corneal allograft immune rejection in vivo
Species
Mouse
Source
Mesenchyaml stromal cells
Condition
Corneal transplantation
Technology
mRNA-seq
Groups
MSCs (mesenchymal stromal cells, n = 3); TGF-β MSCs (licensing murine MSCs with TGF-β, n = 3)
Citation
Lynch, Kevin et al. "TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo." Molecular therapy : the journal of the American Society of Gene Therapy vol. 28,9 (2020): 2023-2043. doi:10.1016/j.ymthe.2020.05.023
